Showing 1 to 21 of 21 results |    
Keyword Search
Results Category/Section
GSK and CureVac in mRNA technology collaboration

GlaxoSmithKline and CureVac are collaborating for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens.

Humane Society International/UK says government must do more to move away from animal use

According to the Humane Society International/UK (HSI/UK), Home Office statistics reveal that the number of animals in British laboratories has stayed broadly the same almost a decade after the government pledged to reduce animal use.

ViiV Healthcare to present new HIV data at International AIDS Conference

Continuing to challenge the current HIV treatment paradigm, data presented will investigate new and innovative treatment options for people living with HIV.

Research highlights public desire for animal alternatives in research

A survey has revealed that 93.4% of respondents think more needs to be done to replace and reduce the use of animals in testing and research.

New antibody internalization advanced screening method provides greater speed & insight

Researchers abilities to improve the breadth of therapeutic antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified early in development.

New President for International Society for Pharmaceutical Engineering

The International Society for Pharmaceutical Engineering (ISPE) has announced the appointment of a new CEO and President.

Horizon Discovery introduces predesigned synthetic sgRNAs to streamline CRISPR gene editing workflows

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range.

Silence For Health - Development of RNA interference based cancer therapy

RNA interference (RNAi) has become an invaluable tool for biomedical research. It is already routinely used as an indispensable approach for gene function analysis in basic biological research and for target identification as well as validation in drug discovery programmes, respectively.

Current Trends in RNA Therapeutics Development

Cellular RNAs play crucial roles during disease progression and represent a diverse and largely untapped class of biomolecules that can be exploited for drug development.

Drug Discovery in the Age of Big Data - The Impact of RNAi & CRISPR/Cas9 Technologies

This article discusses how RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era.

mRNA Will Revolutionise the Biopharmaceutical Industry

Messenger RNA (mRNA) - the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell's DNA into the proteins essential for maintaining cell function and ensuring an organism’s survival, will revolutionise the biopharmaceutical industry.

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference

A decade and a half after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are now starting to emerge for the application of vector-based ddRNAi.

Oncology Target Discovery by RNAi: The past, present, and future perspectives

Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel tumour dependencies and molecular targets.

A Decade of RNAi Screening: Too much hay and very few needles

RNAi screening is arguably the fastest growing field with the premise to better understand gene function at the genome level. It has been hailed as the second genomics wave, and in combination with the human genome-sequencing projects, would constitute the holy grail of modern genetics.

Metabolism Provides Alternative Door to Stroke Therapy

Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs.

RNA interference - A technology platform for target validation, drug discovery and therapeutic development

In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'.

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library

Libraries of siRNAs directed against predefined subsets of genes now offer the capacity to greatly accelerate and improve the quality of functional genomics based drug discovery by enabling a much more targeted approach that effectively integrates the discovery and validation of novel targets.

Functional screening of viral siRNA libraries in human primary cells

One of the major challenges facing the pharmaceutical industry today is the identification and validation of novel, high-quality drugable targets in underserved disease areas.

The Impact of RNAi on Drug Discovery

RNAi (RNA interference) is an important target validation tool that has risen to prominence since 2001. For a number of reasons, it has supplanted other pre-existing target validation tools and is now the method of choice for target validation in cell culture systems.

The market for RNA purification products and services

Purified RNA is crucial for use in a range of downstream applications performed by life scientists, most notably reverse transcription PCR (RT-PCR), quantitative real-time PCR (qPCR) and cDNA synthesis.

Trends in the microRNA Marketplace

In this article, a recent market analysis is discussed aimed at understanding the market landscape, trends and opportunity in the rapidly-expanding microRNA marketplace. These market analyses are presented in detail in a recently published MicroRNA 2008 market report.